Last update Aug. 30, 2018
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
D06AA03; G01AA07; J01AA06; S01AA04 is Oxytetracycline in ATC Code/s.
Is written in other languages:D06AA03; G01AA07; J01AA06; S01AA04 is also known as
D06AA03; G01AA07; J01AA06; S01AA04 belongs to these groups or families:
Main tradenames from several countries containing D06AA03; G01AA07; J01AA06; S01AA04 in its composition:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Derived from tetracycline with similar action and indications.
Systemic oral administration (4 times a day) and also intramuscular.
Topical dermatological, gynecological and ophthalmological administration.
It is excreted in breastmilk in insignificant amounts (Gruner 1955, Ottolenghi 1952).
The intestinal absorption by the infant is greatly diminished by the formation of non-absorbable chelates with dairy calcium (Lactmed 2015, Mitrano 2009, Chin 2001).
No problems have been observed in infants whose mothers were taking it (Gruner 1955).
The possible negativity of cultures in febrile infants whose mothers take antibiotics should be taken into account, as well as the possibility of gastroenteritis due to alteration of the intestinal flora (Ito 1993).
The American Academy of Pediatrics considers tetracycline to be usually compatible with breastfeeding (AAP 2001).
The small dose and low plasma absorption of most topical ophthalmological and dermatological preparations make its transfer in significant amounts into breastmilk even more unlikely.